*유전공학연구원을 포함한 생명과학연구 ***BIOTECH INVESTING
페이지 정보
본문
https://connectbody.com/entry/%EC%83%9D%EB%AA%85%EA%B3%B5%ED%95%99-%EA%B8%B0%EC%88%A0%EC%9D%98-%EC%A0%84%EB%A7%9D
기술의 획기적인 발전과 유전자 조작 작물의 도입으로 2026년까지 세계 시장이 300억 달러에 도달할 것으로 예상된다. 또한 전세계 시장은 예측 기간 동안 5.3%의 CAGR로 확장할 것으로 보인다. 작물 종류 중 옥수수와 콩이 세계에서 가장 큰 비중을 차지할 것으로 예상된다.Mar 4, 2020
유전자조작 시장 2026년까지 300억달러 규모로 성장 - 이미디어http://ecomedia.co.kr › news › newsview
About featured snippets
•
Feedback
유전공학연구원, 하는일과 연봉 및 전망은? - 커리어 Info'shttps://career.fantasy-info.net › ...
·
Translate this page
Dec 25, 2020 — 유전공학연구원를 포함한 생명과학연구원의 종사자 수는 38,000명이며, 향후 10년간 고용은 연평균 2.6% 증가할 것으로 전망된다(자료: 2016~2026 중장기 ...
생명공학 기술의 전망 - 커넥트https://connectbody.com › entry › 생...
·
Translate this page
생명공학 기술의 전망 생명 현상 자체에 포커스를 둔 생명과학과는 달리, 생명공학이란 학문은 생명체의 유전자, 생장 번식에 대한 직접적인 개입에 초점을 둔다.
21세기 생명혁명에 도전한다 ― 생명공학 연구원①https://www.sciencetimes.co.kr › news
·
Translate this page
이처럼 인간의 유전자를 이용한 연구 활동은 유전적 질환치료와 장기이식은 물론 미래 식량자원의 개발 등에 활용되고 있으며, 인류의 건강에 대한 관심이 계속되는 한 생명공학 연구원의 역할과 수요는 늘어날 것이라는 전망이 지배적이다. 필요한 적성과 능력은?
생명공학 동향과 전망 - BRIChttps://www.ibric.org › read
·
Translate this page
Mar 5, 2001 — 또한 최근에 세계적으로 인간유전체해석 연구, 유전자 치료 기술, 뇌과학·뇌공학 연구, 산업미생물·유용작물·가축 등의 유전체 연구, 새로운 생물촉매의 ...
[제1313호] 유전공학의 현재와 미래 - 성대신문http://www.skkuw.com › articleView
·
Translate this page
대부분의 인간 유전자에 대한 기능을 아직 모르고 있는 상황에서 인간 게놈 프로젝트의 발표는 유전자 구조 정보의 이용과 DNA Chip을 비롯한 새로운 고효율 유전자 ...
생명공학의 현황과 전망https://www.forest.go.kr › fms › BoardFileDown
HWP
생명공학의 현황과 전망. (유전자 변형 식물의 안전성 논란에 대하여). 생물공학과장 노은운. 서 론. 1970년대부터 시작된 생명공학은 의료, 농업, 산업, ...
유전공학 기술의 현황과 전망 레포트 - 해피캠퍼스https://www.happycampus.com › rep...
·
Translate this page
4. 생명공학과 유전공학의 인간수명연장방법 1) 인간게놈프로젝트(Human Genome Project) 2) 유전자검사 및 치료법 3) 유전형질전환방법 4) 세포배양공학기술
[4차산업 바이오⑤] 현황과 국내의 생명공학의 발전 전망 < Bio ...http://www.digitalbizon.com › news
·
Translate this page
May 3, 2021 — 신약개발의 작용점이 되는 새로운 단백질이나 유전자를 확보하고 생물학적인 기전에 따라 in vivo 약효 검정과 약물의 기전연구에 적합하게 유전자를 ...
'생명공학·바이오학과' 코로나 종식의 길 연다 [전망 밝은 학과]http://www.edujin.co.kr › articleView
·
Translate this page
May 3, 2021 — 전통적 범위의 바이오산업은 김치, 식초, 요구르트 등의 식품과 농업분야와 연관된것이었다면, 근대적 범위의 바이오산업은 복제 성공이나 유전자재 ...
Related searches
유전공학연구원
유전공학 기술 사례
유전공학과 현실
생명공학자 전망
생명공학자 하는 일
유전공학연구원 하는 일
유전공학자가 하는일
유전공학연구소BIOTECH INVESTING
Top 3 Canadian Biotech Stocks of 2022
Melissa PistilliApr. 26, 2022 01:30PM PSTBIOTECH
test tubes filled with blue liquid
Chokniti Khongchum / Pexels
Which biotech stocks on the CSE, TSXV and TSX are performing the best in 2022? Here’s a look at the five top Canadian biotech stocks.
Click here to read the previous top Canadian biotech stocks article.
Although it’s not as large as the US biotech industry, the Canadian biotech market is still making a name for itself on the global investment stage in terms of size and opportunities.
In recent years, tech advancements in drug research and development have helped the biotech sector worldwide become a “real industry” that has brought “spectacular” returns for mid-cap companies, according to Jessica Chutter, managing director and chairman of biotechnology investment banking with Morgan Stanley (NYSE:MS).
Looking specifically at Canada, in 2021, the country's government committed to investing C$2.2 billion over seven years toward “growing a strong, competitive biomanufacturing and life sciences sector” through a strategy that includes “foster(ing) the growth of Canadian life sciences firms.”
Although 2021 was a rough year for biotech companies, many of the top Canadian biotech stocks managed to perform well, and some have continued that solid performance into 2022.
Below the Investing News Network profiles the three top Canadian biotech stocks on the CSE, TSX and TSXV. Yearly performance and share price data was compiled on April 19, 2022, using TradingView’s stock screener. All top Canadian biotech stocks listed had market caps between C$10 million and C$500 million at that time.
1. Hemostemix (TSXV:HEM)
Market cap: C$20.8 million; year-to-date gain: 128.13 percent
Hemostemix is a clinical-stage autologous stem cell therapy company. Founded in 2003, the firm develops, manufactures and commercializes blood-derived cell therapies from the patient’s own blood.
Hemostemix’s lead product, ACP-01, is designed for the treatment of critical limb ischemia, peripheral artery disease, angina, ischemic cardiomyopathy and dilated cardiomyopathy. Shares of the the top Canadian biotech stock hit a 2022 high point on April 19, clocking in at the C$0.34 level.
2. Fennec Pharmaceuticals (TSX:FRX)
Market cap: C$190.55 million; year-to-date gain: 42.86 percent
Late-stage biopharmaceutical company Fennec Pharmaceuticals is developing cancer drugs. Its lead candidate is PEDMARK, a treatment for pediatric cancer patients experiencing ototoxicity — hearing loss — as a result of platinum-based chemotherapy in pediatric patients.
The drug received breakthrough therapy and fast-track designation from the US Food and Drug Association (FDA) in March 2018. The European Medicines Agency is currently evaluating the marketing authorization application for the sodium thiosulfate-based treatment under the tradename PEDMARQSI. In late March, the company resubmitted its new drug application to the FDA for PEDMARK.
Company shares reached a year-to-date high of C$8 on April 14.
3. Antibe Therapeutics (TSX:ATE)
Market cap: C$40.98 million; year-to-date gain: 16.67 percent
Antibe Therapeutics is a clinical-stage biotech firm leveraging its proprietary hydrogen sulfide platform to develop safer pain and inflammation-reducing drugs. The company’s pipeline includes drug candidates that don’t bring about the gastrointestinal ulcers and bleeding associated with non-steroidal anti-inflammatory drugs (NSAIDs).
Antibe’s drug candidates under development include otenaproxesul, a safer alternative to opioids and NSAIDs for post-operative pain, and ATB-352 for a specialized pain indication. The company also plans to target inflammatory bowel disease with safer, more effective therapies. Shares marked a high of C$0.80 on March 28.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
What is the biotech sector?
Biotechnology is a science-driven industry sector that uses living organisms and molecular biology to produce healthcare-related products. Biotechnology companies also develop therapeutics or processes (such as DNA fingerprinting).
What are the various sectors of biotechnology industry?
Biotechnology companies are those that employ living organisms or biological substances for the development of products and services with applications in numerous fields such as waste management, food processing, agriculture and pharmaceutics.
What are the 4 types of biotechnology?
Image result
Types of Biotechnology
Medical Biotechnology. Medical biotechnology is the use of living cells and other cell materials to better the health of humans. ...
Agricultural Biotechnology. ...
Industrial Biotechnology. ...
Environmental Biotechnology.
Best biotech stocks
These are a few biotech companies to watch closely in 2022:
Company Market Capitalization Primary focus
Axsome Therapeutics (NASDAQ:AXSM) $1.08 billion Neuroscience
Exelixis (NASDAQ:EXEL) $5.7 billion Cancer
Novavax (NASDAQ:NVAX) $8.4 billion Infectious diseases
Regeneron Pharmaceuticals (NASDAQ:REGN) $66.2 billion Autoimmune diseases, cancer, eye diseases, infectious diseases
Vertex Pharmaceuticals (NASDAQ:VRTX) $59.5 billion Rare diseases, diabetes
Twist Bioscience NASDAQ:TWST) $3.03 billion Synthetic DNA
Data sources: Yahoo! Finance, company websites. Market caps as of Jan. 18, 2022.
1. Axsome Therapeutics
Axsome's lead drug candidate, which it calls AXS-05, targets depression, Alzheimer’s disease-related agitation, and cigarette smoking cessation. In early 2021, the company filed for U.S. regulatory approval for the drug to treat depression. The U.S. Food and Drug Administration (FDA) identified two manufacturing deficiencies in Axsome’s regulatory filing, but Axsome believes the issues are addressable and is working with the FDA to resolve them.
The company’s pipeline includes two other late-stage candidates. AXS-07 targets the treatment of migraines, and the FDA is scheduled to make an approval decision on the investigational drug in 2022. In 2023, Axsome expects to file for U.S. regulatory approval of AXS-14 for treating fibromyalgia.
If approved, AXS-05 as a depression treatment could be a blockbuster drug, with peak annual sales -- the highest dollar volume of sales per year projected by analysts -- estimated at $2.6 billion. The peak annual sales forecast for AXS-07 in the U.S. alone is more than $500 million per year. Analysts think that AXS-14, if approved, could generate peak sales of between $500 million and $1 billion. The revenue potential for these three drug candidates makes Axsome Therapeutics an attractive biotech stock to consider buying in 2022.
2. Exelixis
Exelixis has four drugs that are already on the market. Its biggest winner by far is Cabometyx, which is approved to treat renal cell carcinoma (RCC) and hepatocellular carcinoma (HC) -- the most common types of kidney cancer and liver cancer, respectively – as well as thyroid cancer.
Exelixis and biopharma company Bristol Myers Squibb (NYSE:BMY) won U.S. regulatory approval in early 2021 for the use of Cabometyx in combination with Bristol Myers' immunotherapy drug Opdivo. Exelixis is also working with drugmaker Roche (OTC:RHHBY) to evaluate a combination treatment using Cabometyx and Roche's cancer immunotherapy treatment Tecentriq. Both of these treatment combinations are targeting previously untreated RCC.
Exelixis is profitable, which enables it to use its fast-growing cash stockpile to enter into new licensing agreements and otherwise expand its drug offerings. It licenses from the development-stage biotech company Aurigene the right to further develop a promising early-stage cancer drug called XL102, and, from WuXi Biologics, the company licenses a panel of monoclonal antibodies. Exelixis also acquired GamaMabs Pharma’s anti-Müllerian hormone receptor 2 (AMHR2) antibody programs.
3. Novavax
Novavax is developing a COVID-19 vaccine candidate that it calls NVX-CoV2373. Its vaccine candidate uses a single protein molecule, known as a protein subunit, to spur an immune response against the novel coronavirus.
NVX-CoV2373 has already secured authorizations or approvals in the European Union, India, Indonesia, the Philippines, and South Korea. The vaccine also received an Emergency Use Listing (EUL) from the World Health Organization. The EUL is an important prerequisite for distribution to countries that participate in the COVAX Facility, which works to ensure access to COVID-19 vaccines for low- and middle-income nations. Novavax hopes to gain additional regulatory wins in 2022, including in the U.S.
In 2020, Novavax reported positive results from its late-stage testing of an experimental flu vaccine called NanoFlu. The company is developing a combination COVID-19/flu vaccine using both NVX-CoV2373 and NanoFlu. Novavax expects to report results from a phase 1/2 study of this combo vaccine in the first half of 2022.
4. Regeneron Pharmaceuticals
The biggest moneymaker for Regeneron is Eylea, an eye disease drug that the company makes in collaboration with Bayer (OTC:BAYRY). All net sales from Eylea in the U.S. are awarded to Regeneron, and the company splits with Bayer the revenue earned from markets outside the U.S.
Regeneron also has a lucrative partnership with Sanofi (NASDAQ:SNY), another life sciences and pharmaceutical company. Together, the two companies are marketing and selling the autoimmune disease drugs Dupixent and Kevzara, the cancer drugs Libtayo and Zaltrap, and the cholesterol drug Praluent.
REGEN-COV, a monoclonal antibody therapy for COVID-19, has been a huge commercial success for Regeneron so far. Regeneron distributes the therapy in the U.S., while its partner Roche distributes it outside the U.S. REGEN-COV doesn’t appear to be as effective against the coronavirus omicron variant. However, Regeneron is developing new antibody therapies to target the highly transmissible strain.
Several of Regeneron’s drug development programs are focused on gaining approvals for new indications for already approved drugs. The company also is developing new drug candidates, notably including the experimental gene-editing therapy NTLA-2001, which Regeneron is developing in partnership with Intellia Therapeutics (NASDAQ:NTLA).
5. Vertex Pharmaceuticals
Vertex, which makes multiple cystic fibrosis (CF) drugs, enjoys a near-total monopoly over sales of treatments for the underlying cause of CF. Its newest drug, a combination of the two CF drugs Trikafta and Kaftrio, could expand Vertex's addressable cystic fibrosis patient population by more than 50%. The company’s pipeline also includes other promising CF drugs in phase 2 testing.
Vertex is seeking to expand beyond CF treatments with phase 2 programs targeting pain and kidney diseases caused by specific gene mutations. Vertex is also pursuing an early-stage development program in partnership with CRISPR Therapeutics (NASDAQ:CRSP) to test gene-editing therapies that target the rare blood diseases beta-thalassemia and sickle cell disease. In addition, the company has advanced its clinical testing of an experimental drug that has the potential to cure type 1 diabetes in some patients.
Vertex is already profitable, which gives it a large cash stockpile that it can use to further bolster its drug candidate pipeline.
What is the largest biotechnology company?
How many biotech companies are there in Canada?
It accounts for 661 companies and research organisms in the life science sector that employs 37,250 people. Of the 146 biotechnology companies located in Quebec, 102 are located in the Greater Montreal Region employing more than 2,590 field-related people.Mar 31, 2005
All
NewsShoppingVideosImagesMore
Tools
Issuers
/
Biotechnology
/
Stock
Feedback
Best Biotech Stocks to Buy in 2022 | The Motley Foolhttps://www.fool.com › market-sectors › healthcare › bi...
5 days ago — Best biotech stocks ; Axsome Therapeutics (NASDAQ:AXSM), $1.08 billion, Neuroscience ; Exelixis (NASDAQ:EXEL), $5.7 billion, Cancer ; Novavax ( ...
Axsome Therapeutics - AXSM · Nasdaq:exel · Nasdaq:twst
People also ask
What is best biotech stock?
Is biotech good to invest?
What is biotech stock today?
What biotech stocks are selling for $5?
Feedback
Top Biotech Stocks for Q2 2022 - Investopediahttps://www.investopedia.com › investing › biotech-sto...
Biotech Stocks with the Most Momentum ; Aadi Bioscience Inc. (AADI), 18.39, 0.4 ; Liquidia Corp. (LQDA), 7.35, 0.4 ; Iveric Bio Inc. (ISEE), 16.61, 1.9 ; Russell ...
8 Best Biotech Stocks to Buy in 2022 | Investing | US Newshttps://money.usnews.com › Money › Investing
The following eight biotech stocks all carry risk, however a number of them have actually moved higher, even in this tough market. Next:Alkermes PLC (ticker:.
Biotech Stocks - Intra-day price/vol movers • BioPharmCatalysthttps://www.biopharmcatalyst.com › biotech-stocks
Search 600 Biotech stocks listed on NYSE/NASDAQ - drug pipelines, key upcoming biotech catalysts, price movers, charts, news and SEC filings.
Biotech Stocks To Watch And Pharma Industry Newshttps://www.investors.com › news › technology › biote...
23 hours ago — Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
Top 3 Canadian Biotech Stocks of 2022 | INN - Investing News ...https://investingnews.com › daily › life-science-investing
Apr 26, 2022 — Shares of the the top Canadian biotech stock hit a 2022 high point on April 19, clocking in at the C$0.34 level. 2. Fennec Pharmaceuticals (TSX: ...
7 Best Biotech Stocks to Build Your Portfolio | Kiplingerhttps://www.kiplinger.com › investing › stocks
Apr 26, 2022 — Investing in biotech stocks can be tricky due to their volatile nature. That's why we turned to Wall Street's pros to find these top-rated picks ...
Biotech Stocks Are Still Falling. The Near-Term Outlook Is Grim.https://www.barrons.com › articles › biotech-stocks-outlo...
5 days ago — For biotech stocks this year, April really was the cruelest month. The SPDR S&P Biotech exchange-traded fund (ticker: XBI) fell 17.9% in ...
12 biotech stocks to consider buying now as prospects for the ...https://www.marketwatch.com › Investing
Feb 6, 2022 — Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double ...
10 Best Biotech Stocks To Buy For 2021 - Yahoo Financehttps://finance.yahoo.com › news › 10-best-biotech-sto...
Apr 5, 2021 — 10 Best Biotech Stocks To Buy For 2021 · pursuing biotechnology stocks in the hopes of a rapid surge in value as vaccine research moved ahead.
Related searches
Apellis Pharmace...
Vaxart
Karuna Therapeuti...
Genfit
Cassava Sciences
Verastem Oncology
See more
Feedback
newlimit biotech stock
biotech stock price list
biotech stock symbol
how to buy biotech stock
biotech stock price today
biotech stocks list
biotech stocks today
biotech stock for 2022
https://www.google.ca/search?q=biotech+stock&dcr=0&sxsrf=ALiCzsa3dglaENZS-tXYHnh5zCLAJ_Y2ag%3A1651921793893&ei=gVN2YoOPNsbC0PEPsZSEmAw&ved=0ahUKEwjD0-KdoM33AhVGITQIHTEKAcMQ4dUDCA4&oq=biotech+stock&gs_lcp=Cgdnd3Mtd2l6EAwyBwgAEE
cQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMy
BwgAEEcQsAMyBwgAEEcQsAMyBwgAELADEEMyBwgAELADEEMyBwgAELADEEMyBwgA
ELADEEMyCggAEOQCELADGAEyCggAEOQCELADGAEyCggAEOQCELADGAEyEgguEMcB
EKMCEMgDELADEEMYAjISCC4QxwEQ0QMQyAMQsAMQQxgCMhIILhDHARDRAxDIAxCwAxBD
GAJKBAhBGABKBAhGGAFQAFgAYJYnaAFwAXgAgAEAiAEAkgEAmAEAyAESwAEB2gEGCAE
QARgJ2gEGCAIQARgI&sclient=gws-wiz
* 최종수정일 : 2022.05.07 <21:00>
기술의 획기적인 발전과 유전자 조작 작물의 도입으로 2026년까지 세계 시장이 300억 달러에 도달할 것으로 예상된다. 또한 전세계 시장은 예측 기간 동안 5.3%의 CAGR로 확장할 것으로 보인다. 작물 종류 중 옥수수와 콩이 세계에서 가장 큰 비중을 차지할 것으로 예상된다.Mar 4, 2020
유전자조작 시장 2026년까지 300억달러 규모로 성장 - 이미디어http://ecomedia.co.kr › news › newsview
About featured snippets
•
Feedback
유전공학연구원, 하는일과 연봉 및 전망은? - 커리어 Info'shttps://career.fantasy-info.net › ...
·
Translate this page
Dec 25, 2020 — 유전공학연구원를 포함한 생명과학연구원의 종사자 수는 38,000명이며, 향후 10년간 고용은 연평균 2.6% 증가할 것으로 전망된다(자료: 2016~2026 중장기 ...
생명공학 기술의 전망 - 커넥트https://connectbody.com › entry › 생...
·
Translate this page
생명공학 기술의 전망 생명 현상 자체에 포커스를 둔 생명과학과는 달리, 생명공학이란 학문은 생명체의 유전자, 생장 번식에 대한 직접적인 개입에 초점을 둔다.
21세기 생명혁명에 도전한다 ― 생명공학 연구원①https://www.sciencetimes.co.kr › news
·
Translate this page
이처럼 인간의 유전자를 이용한 연구 활동은 유전적 질환치료와 장기이식은 물론 미래 식량자원의 개발 등에 활용되고 있으며, 인류의 건강에 대한 관심이 계속되는 한 생명공학 연구원의 역할과 수요는 늘어날 것이라는 전망이 지배적이다. 필요한 적성과 능력은?
생명공학 동향과 전망 - BRIChttps://www.ibric.org › read
·
Translate this page
Mar 5, 2001 — 또한 최근에 세계적으로 인간유전체해석 연구, 유전자 치료 기술, 뇌과학·뇌공학 연구, 산업미생물·유용작물·가축 등의 유전체 연구, 새로운 생물촉매의 ...
[제1313호] 유전공학의 현재와 미래 - 성대신문http://www.skkuw.com › articleView
·
Translate this page
대부분의 인간 유전자에 대한 기능을 아직 모르고 있는 상황에서 인간 게놈 프로젝트의 발표는 유전자 구조 정보의 이용과 DNA Chip을 비롯한 새로운 고효율 유전자 ...
생명공학의 현황과 전망https://www.forest.go.kr › fms › BoardFileDown
HWP
생명공학의 현황과 전망. (유전자 변형 식물의 안전성 논란에 대하여). 생물공학과장 노은운. 서 론. 1970년대부터 시작된 생명공학은 의료, 농업, 산업, ...
유전공학 기술의 현황과 전망 레포트 - 해피캠퍼스https://www.happycampus.com › rep...
·
Translate this page
4. 생명공학과 유전공학의 인간수명연장방법 1) 인간게놈프로젝트(Human Genome Project) 2) 유전자검사 및 치료법 3) 유전형질전환방법 4) 세포배양공학기술
[4차산업 바이오⑤] 현황과 국내의 생명공학의 발전 전망 < Bio ...http://www.digitalbizon.com › news
·
Translate this page
May 3, 2021 — 신약개발의 작용점이 되는 새로운 단백질이나 유전자를 확보하고 생물학적인 기전에 따라 in vivo 약효 검정과 약물의 기전연구에 적합하게 유전자를 ...
'생명공학·바이오학과' 코로나 종식의 길 연다 [전망 밝은 학과]http://www.edujin.co.kr › articleView
·
Translate this page
May 3, 2021 — 전통적 범위의 바이오산업은 김치, 식초, 요구르트 등의 식품과 농업분야와 연관된것이었다면, 근대적 범위의 바이오산업은 복제 성공이나 유전자재 ...
Related searches
유전공학연구원
유전공학 기술 사례
유전공학과 현실
생명공학자 전망
생명공학자 하는 일
유전공학연구원 하는 일
유전공학자가 하는일
유전공학연구소BIOTECH INVESTING
Top 3 Canadian Biotech Stocks of 2022
Melissa PistilliApr. 26, 2022 01:30PM PSTBIOTECH
test tubes filled with blue liquid
Chokniti Khongchum / Pexels
Which biotech stocks on the CSE, TSXV and TSX are performing the best in 2022? Here’s a look at the five top Canadian biotech stocks.
Click here to read the previous top Canadian biotech stocks article.
Although it’s not as large as the US biotech industry, the Canadian biotech market is still making a name for itself on the global investment stage in terms of size and opportunities.
In recent years, tech advancements in drug research and development have helped the biotech sector worldwide become a “real industry” that has brought “spectacular” returns for mid-cap companies, according to Jessica Chutter, managing director and chairman of biotechnology investment banking with Morgan Stanley (NYSE:MS).
Looking specifically at Canada, in 2021, the country's government committed to investing C$2.2 billion over seven years toward “growing a strong, competitive biomanufacturing and life sciences sector” through a strategy that includes “foster(ing) the growth of Canadian life sciences firms.”
Although 2021 was a rough year for biotech companies, many of the top Canadian biotech stocks managed to perform well, and some have continued that solid performance into 2022.
Below the Investing News Network profiles the three top Canadian biotech stocks on the CSE, TSX and TSXV. Yearly performance and share price data was compiled on April 19, 2022, using TradingView’s stock screener. All top Canadian biotech stocks listed had market caps between C$10 million and C$500 million at that time.
1. Hemostemix (TSXV:HEM)
Market cap: C$20.8 million; year-to-date gain: 128.13 percent
Hemostemix is a clinical-stage autologous stem cell therapy company. Founded in 2003, the firm develops, manufactures and commercializes blood-derived cell therapies from the patient’s own blood.
Hemostemix’s lead product, ACP-01, is designed for the treatment of critical limb ischemia, peripheral artery disease, angina, ischemic cardiomyopathy and dilated cardiomyopathy. Shares of the the top Canadian biotech stock hit a 2022 high point on April 19, clocking in at the C$0.34 level.
2. Fennec Pharmaceuticals (TSX:FRX)
Market cap: C$190.55 million; year-to-date gain: 42.86 percent
Late-stage biopharmaceutical company Fennec Pharmaceuticals is developing cancer drugs. Its lead candidate is PEDMARK, a treatment for pediatric cancer patients experiencing ototoxicity — hearing loss — as a result of platinum-based chemotherapy in pediatric patients.
The drug received breakthrough therapy and fast-track designation from the US Food and Drug Association (FDA) in March 2018. The European Medicines Agency is currently evaluating the marketing authorization application for the sodium thiosulfate-based treatment under the tradename PEDMARQSI. In late March, the company resubmitted its new drug application to the FDA for PEDMARK.
Company shares reached a year-to-date high of C$8 on April 14.
3. Antibe Therapeutics (TSX:ATE)
Market cap: C$40.98 million; year-to-date gain: 16.67 percent
Antibe Therapeutics is a clinical-stage biotech firm leveraging its proprietary hydrogen sulfide platform to develop safer pain and inflammation-reducing drugs. The company’s pipeline includes drug candidates that don’t bring about the gastrointestinal ulcers and bleeding associated with non-steroidal anti-inflammatory drugs (NSAIDs).
Antibe’s drug candidates under development include otenaproxesul, a safer alternative to opioids and NSAIDs for post-operative pain, and ATB-352 for a specialized pain indication. The company also plans to target inflammatory bowel disease with safer, more effective therapies. Shares marked a high of C$0.80 on March 28.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
What is the biotech sector?
Biotechnology is a science-driven industry sector that uses living organisms and molecular biology to produce healthcare-related products. Biotechnology companies also develop therapeutics or processes (such as DNA fingerprinting).
What are the various sectors of biotechnology industry?
Biotechnology companies are those that employ living organisms or biological substances for the development of products and services with applications in numerous fields such as waste management, food processing, agriculture and pharmaceutics.
What are the 4 types of biotechnology?
Image result
Types of Biotechnology
Medical Biotechnology. Medical biotechnology is the use of living cells and other cell materials to better the health of humans. ...
Agricultural Biotechnology. ...
Industrial Biotechnology. ...
Environmental Biotechnology.
Best biotech stocks
These are a few biotech companies to watch closely in 2022:
Company Market Capitalization Primary focus
Axsome Therapeutics (NASDAQ:AXSM) $1.08 billion Neuroscience
Exelixis (NASDAQ:EXEL) $5.7 billion Cancer
Novavax (NASDAQ:NVAX) $8.4 billion Infectious diseases
Regeneron Pharmaceuticals (NASDAQ:REGN) $66.2 billion Autoimmune diseases, cancer, eye diseases, infectious diseases
Vertex Pharmaceuticals (NASDAQ:VRTX) $59.5 billion Rare diseases, diabetes
Twist Bioscience NASDAQ:TWST) $3.03 billion Synthetic DNA
Data sources: Yahoo! Finance, company websites. Market caps as of Jan. 18, 2022.
1. Axsome Therapeutics
Axsome's lead drug candidate, which it calls AXS-05, targets depression, Alzheimer’s disease-related agitation, and cigarette smoking cessation. In early 2021, the company filed for U.S. regulatory approval for the drug to treat depression. The U.S. Food and Drug Administration (FDA) identified two manufacturing deficiencies in Axsome’s regulatory filing, but Axsome believes the issues are addressable and is working with the FDA to resolve them.
The company’s pipeline includes two other late-stage candidates. AXS-07 targets the treatment of migraines, and the FDA is scheduled to make an approval decision on the investigational drug in 2022. In 2023, Axsome expects to file for U.S. regulatory approval of AXS-14 for treating fibromyalgia.
If approved, AXS-05 as a depression treatment could be a blockbuster drug, with peak annual sales -- the highest dollar volume of sales per year projected by analysts -- estimated at $2.6 billion. The peak annual sales forecast for AXS-07 in the U.S. alone is more than $500 million per year. Analysts think that AXS-14, if approved, could generate peak sales of between $500 million and $1 billion. The revenue potential for these three drug candidates makes Axsome Therapeutics an attractive biotech stock to consider buying in 2022.
2. Exelixis
Exelixis has four drugs that are already on the market. Its biggest winner by far is Cabometyx, which is approved to treat renal cell carcinoma (RCC) and hepatocellular carcinoma (HC) -- the most common types of kidney cancer and liver cancer, respectively – as well as thyroid cancer.
Exelixis and biopharma company Bristol Myers Squibb (NYSE:BMY) won U.S. regulatory approval in early 2021 for the use of Cabometyx in combination with Bristol Myers' immunotherapy drug Opdivo. Exelixis is also working with drugmaker Roche (OTC:RHHBY) to evaluate a combination treatment using Cabometyx and Roche's cancer immunotherapy treatment Tecentriq. Both of these treatment combinations are targeting previously untreated RCC.
Exelixis is profitable, which enables it to use its fast-growing cash stockpile to enter into new licensing agreements and otherwise expand its drug offerings. It licenses from the development-stage biotech company Aurigene the right to further develop a promising early-stage cancer drug called XL102, and, from WuXi Biologics, the company licenses a panel of monoclonal antibodies. Exelixis also acquired GamaMabs Pharma’s anti-Müllerian hormone receptor 2 (AMHR2) antibody programs.
3. Novavax
Novavax is developing a COVID-19 vaccine candidate that it calls NVX-CoV2373. Its vaccine candidate uses a single protein molecule, known as a protein subunit, to spur an immune response against the novel coronavirus.
NVX-CoV2373 has already secured authorizations or approvals in the European Union, India, Indonesia, the Philippines, and South Korea. The vaccine also received an Emergency Use Listing (EUL) from the World Health Organization. The EUL is an important prerequisite for distribution to countries that participate in the COVAX Facility, which works to ensure access to COVID-19 vaccines for low- and middle-income nations. Novavax hopes to gain additional regulatory wins in 2022, including in the U.S.
In 2020, Novavax reported positive results from its late-stage testing of an experimental flu vaccine called NanoFlu. The company is developing a combination COVID-19/flu vaccine using both NVX-CoV2373 and NanoFlu. Novavax expects to report results from a phase 1/2 study of this combo vaccine in the first half of 2022.
4. Regeneron Pharmaceuticals
The biggest moneymaker for Regeneron is Eylea, an eye disease drug that the company makes in collaboration with Bayer (OTC:BAYRY). All net sales from Eylea in the U.S. are awarded to Regeneron, and the company splits with Bayer the revenue earned from markets outside the U.S.
Regeneron also has a lucrative partnership with Sanofi (NASDAQ:SNY), another life sciences and pharmaceutical company. Together, the two companies are marketing and selling the autoimmune disease drugs Dupixent and Kevzara, the cancer drugs Libtayo and Zaltrap, and the cholesterol drug Praluent.
REGEN-COV, a monoclonal antibody therapy for COVID-19, has been a huge commercial success for Regeneron so far. Regeneron distributes the therapy in the U.S., while its partner Roche distributes it outside the U.S. REGEN-COV doesn’t appear to be as effective against the coronavirus omicron variant. However, Regeneron is developing new antibody therapies to target the highly transmissible strain.
Several of Regeneron’s drug development programs are focused on gaining approvals for new indications for already approved drugs. The company also is developing new drug candidates, notably including the experimental gene-editing therapy NTLA-2001, which Regeneron is developing in partnership with Intellia Therapeutics (NASDAQ:NTLA).
5. Vertex Pharmaceuticals
Vertex, which makes multiple cystic fibrosis (CF) drugs, enjoys a near-total monopoly over sales of treatments for the underlying cause of CF. Its newest drug, a combination of the two CF drugs Trikafta and Kaftrio, could expand Vertex's addressable cystic fibrosis patient population by more than 50%. The company’s pipeline also includes other promising CF drugs in phase 2 testing.
Vertex is seeking to expand beyond CF treatments with phase 2 programs targeting pain and kidney diseases caused by specific gene mutations. Vertex is also pursuing an early-stage development program in partnership with CRISPR Therapeutics (NASDAQ:CRSP) to test gene-editing therapies that target the rare blood diseases beta-thalassemia and sickle cell disease. In addition, the company has advanced its clinical testing of an experimental drug that has the potential to cure type 1 diabetes in some patients.
Vertex is already profitable, which gives it a large cash stockpile that it can use to further bolster its drug candidate pipeline.
What is the largest biotechnology company?
How many biotech companies are there in Canada?
It accounts for 661 companies and research organisms in the life science sector that employs 37,250 people. Of the 146 biotechnology companies located in Quebec, 102 are located in the Greater Montreal Region employing more than 2,590 field-related people.Mar 31, 2005
All
NewsShoppingVideosImagesMore
Tools
Issuers
/
Biotechnology
/
Stock
Feedback
Best Biotech Stocks to Buy in 2022 | The Motley Foolhttps://www.fool.com › market-sectors › healthcare › bi...
5 days ago — Best biotech stocks ; Axsome Therapeutics (NASDAQ:AXSM), $1.08 billion, Neuroscience ; Exelixis (NASDAQ:EXEL), $5.7 billion, Cancer ; Novavax ( ...
Axsome Therapeutics - AXSM · Nasdaq:exel · Nasdaq:twst
People also ask
What is best biotech stock?
Is biotech good to invest?
What is biotech stock today?
What biotech stocks are selling for $5?
Feedback
Top Biotech Stocks for Q2 2022 - Investopediahttps://www.investopedia.com › investing › biotech-sto...
Biotech Stocks with the Most Momentum ; Aadi Bioscience Inc. (AADI), 18.39, 0.4 ; Liquidia Corp. (LQDA), 7.35, 0.4 ; Iveric Bio Inc. (ISEE), 16.61, 1.9 ; Russell ...
8 Best Biotech Stocks to Buy in 2022 | Investing | US Newshttps://money.usnews.com › Money › Investing
The following eight biotech stocks all carry risk, however a number of them have actually moved higher, even in this tough market. Next:Alkermes PLC (ticker:.
Biotech Stocks - Intra-day price/vol movers • BioPharmCatalysthttps://www.biopharmcatalyst.com › biotech-stocks
Search 600 Biotech stocks listed on NYSE/NASDAQ - drug pipelines, key upcoming biotech catalysts, price movers, charts, news and SEC filings.
Biotech Stocks To Watch And Pharma Industry Newshttps://www.investors.com › news › technology › biote...
23 hours ago — Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
Top 3 Canadian Biotech Stocks of 2022 | INN - Investing News ...https://investingnews.com › daily › life-science-investing
Apr 26, 2022 — Shares of the the top Canadian biotech stock hit a 2022 high point on April 19, clocking in at the C$0.34 level. 2. Fennec Pharmaceuticals (TSX: ...
7 Best Biotech Stocks to Build Your Portfolio | Kiplingerhttps://www.kiplinger.com › investing › stocks
Apr 26, 2022 — Investing in biotech stocks can be tricky due to their volatile nature. That's why we turned to Wall Street's pros to find these top-rated picks ...
Biotech Stocks Are Still Falling. The Near-Term Outlook Is Grim.https://www.barrons.com › articles › biotech-stocks-outlo...
5 days ago — For biotech stocks this year, April really was the cruelest month. The SPDR S&P Biotech exchange-traded fund (ticker: XBI) fell 17.9% in ...
12 biotech stocks to consider buying now as prospects for the ...https://www.marketwatch.com › Investing
Feb 6, 2022 — Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double ...
10 Best Biotech Stocks To Buy For 2021 - Yahoo Financehttps://finance.yahoo.com › news › 10-best-biotech-sto...
Apr 5, 2021 — 10 Best Biotech Stocks To Buy For 2021 · pursuing biotechnology stocks in the hopes of a rapid surge in value as vaccine research moved ahead.
Related searches
Apellis Pharmace...
Vaxart
Karuna Therapeuti...
Genfit
Cassava Sciences
Verastem Oncology
See more
Feedback
newlimit biotech stock
biotech stock price list
biotech stock symbol
how to buy biotech stock
biotech stock price today
biotech stocks list
biotech stocks today
biotech stock for 2022
https://www.google.ca/search?q=biotech+stock&dcr=0&sxsrf=ALiCzsa3dglaENZS-tXYHnh5zCLAJ_Y2ag%3A1651921793893&ei=gVN2YoOPNsbC0PEPsZSEmAw&ved=0ahUKEwjD0-KdoM33AhVGITQIHTEKAcMQ4dUDCA4&oq=biotech+stock&gs_lcp=Cgdnd3Mtd2l6EAwyBwgAEE
cQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMy
BwgAEEcQsAMyBwgAEEcQsAMyBwgAELADEEMyBwgAELADEEMyBwgAELADEEMyBwgA
ELADEEMyCggAEOQCELADGAEyCggAEOQCELADGAEyCggAEOQCELADGAEyEgguEMcB
EKMCEMgDELADEEMYAjISCC4QxwEQ0QMQyAMQsAMQQxgCMhIILhDHARDRAxDIAxCwAxBD
GAJKBAhBGABKBAhGGAFQAFgAYJYnaAFwAXgAgAEAiAEAkgEAmAEAyAESwAEB2gEGCAE
QARgJ2gEGCAIQARgI&sclient=gws-wiz
* 최종수정일 : 2022.05.07 <21:00>
- 이전글유전자 치료 미래--DNA FUTURE 미래--퇴행성관절염 치료제, 항암 세포 유전자치료제, 면역세포 유전자치료제 17.01.27
- 다음글크리스퍼 유전자 가위 (CRISPR, Clustered regularly interspaced short palindromic repeats) 17.11.06
댓글목록
등록된 댓글이 없습니다.